Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1985 3
1986 1
1987 1
1988 3
1989 2
1990 5
1993 1
1994 6
1995 4
1996 4
1997 5
1998 6
1999 1
2000 4
2001 8
2002 2
2003 4
2004 3
2005 4
2006 4
2007 8
2008 10
2009 11
2010 9
2011 8
2012 13
2013 15
2014 10
2015 15
2016 10
2017 6
2018 11
2019 13
2020 8
2021 10
2022 9
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Clear Cell Renal Cell Carcinoma"
Page 1
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Balar AV, et al. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Lancet Oncol. 2017. PMID: 28967485 Clinical Trial.
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. ...Pembrolizumab in the first-line setting is being fu …
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy …
Sunitinib.
Heng DY, Kollmannsberger C. Heng DY, et al. Recent Results Cancer Res. 2010;184:71-82. doi: 10.1007/978-3-642-01222-8_6. Recent Results Cancer Res. 2010. PMID: 20072832 Review.
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestinal stromal tumors (GIST). ...This chapter will detail the preclinical data leading to the results of the pivotal pha …
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresec …
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Yan XQ, et al. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37872020 Free article. Clinical Trial.
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab pl …
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear …
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS: In the …
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HN …
Sunitinib.
Deeks ED, Keating GM. Deeks ED, et al. Drugs. 2006;66(17):2255-66; discussion 2267-8. doi: 10.2165/00003495-200666170-00007. Drugs. 2006. PMID: 17137406 Review.
In a phase III, randomised, double-blind, placebo-controlled, multicentre trial in patients with metastatic and/or unresectable GIST following unsuccessful imatinib therapy, the median time to tumour progression and median progression-free survival time were …
In a phase III, randomised, double-blind, placebo-controlled, multicentre trial in patients with metastatic and/or unresect …
Immunotherapy-based combinations: an update.
Fucà G, de Braud F, Di Nicola M. Fucà G, et al. Curr Opin Oncol. 2018 Sep;30(5):345-351. doi: 10.1097/CCO.0000000000000466. Curr Opin Oncol. 2018. PMID: 29994900 Review.
PURPOSE OF REVIEW: The advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoint blockade (ICB) still lack of efficacy in a consistent proportion of treated patients. ...RECENT FINDINGS: First-line combinatorial treatme …
PURPOSE OF REVIEW: The advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoin …
Surgical management of metastatic renal cell carcinoma.
Ball MW. Ball MW. Discov Med. 2017 Jun;23(129):379-387. Discov Med. 2017. PMID: 28877449 Free article. Review.
Despite advances in systemic therapy for metastatic renal cell carcinoma, durable responses remain rare and surgical management remains a mainstay of treatment for many patients with metastatic disease. ...Herein, the evidence for surgical management of both …
Despite advances in systemic therapy for metastatic renal cell carcinoma, durable responses remain rare and surgical ma …
Combined use of pembrolizumab and lenvatinib: A review.
Eisinger C, Muluneh B. Eisinger C, et al. J Oncol Pharm Pract. 2023 Sep;29(6):1461-1466. doi: 10.1177/10781552231178461. Epub 2023 May 25. J Oncol Pharm Pract. 2023. PMID: 37231712 Free PMC article. Review.
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal carcinoma in patients with favorable risk or intermediate/poor risk and in endometrial carcinoma as a preferred second-line regi …
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal …
Lenvatinib-related renal microangiopathy: a case series.
Delsante M, Monroy-Trujillo JM, Carter-Monroe N, Ball DW, Rosenberg AZ. Delsante M, et al. Virchows Arch. 2022 Feb;480(2):467-473. doi: 10.1007/s00428-021-03114-5. Epub 2021 May 6. Virchows Arch. 2022. PMID: 33959820
Lenvatinib is a multiple kinase inhibitor approved by the Food and Drugs Administration (FDA) for the treatment of advanced and radioresistant thyroid carcinomas and, in combination with everolimus, for renal cell carcinoma and unresectable hepatocellu …
Lenvatinib is a multiple kinase inhibitor approved by the Food and Drugs Administration (FDA) for the treatment of advanced and radioresista …
Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.
Roy AM, Briggler A, Tippit D, Dawson K, Verma R. Roy AM, et al. Clin Genitourin Cancer. 2020 Dec;18(6):e688-e691. doi: 10.1016/j.clgc.2020.04.003. Epub 2020 Apr 21. Clin Genitourin Cancer. 2020. PMID: 32660880 Review.
Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable disease, tumor may be shrunk by using chemotherapy, thereby permitting surgical resection, which can be curative. We provided neoadjuvant cab …
Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable d …
225 results